Jaguar Health, INC

Jaguar Health, Inc. has exchanged a portion of its outstanding debt for shares of its common stock, reducing its principal balance by $3.4 million.

Jaguar Health, Inc. has exchanged a portion of its outstanding secured promissory note for shares of its common stock, reducing its debt balance.

Jaguar Health, Inc. has filed a Form 8-K detailing the elimination of multiple series of preferred stock and the completion of a 1-for-15 reverse stock split.

Jaguar Health, Inc. has entered into multiple agreements to exchange outstanding debt for common stock and pre-funded warrants, impacting its capital structure.

Jaguar Health, Inc. announced the effectuation of a 1-for-15 reverse stock split, effective September 17, 2026, to comply with Nasdaq listing standards.

Jaguar Health announced its second quarter 2026 financial results, reporting a 59% decrease in total revenue to $1.2 million and a widened net loss of $12.7 million.

Jaguar Health reported substantial net losses and an accumulated deficit, raising going concern doubts, though a recent licensing agreement provided a significant revenue boost.

Jaguar Health Inc. reported a significant increase in revenue for Q1 2026, primarily driven by a new licensing agreement, while managing operating expenses and advancing its pipeline.

Jaguar Health reports increased net losses and negative cash flows for Q3 2025, raising substantial doubt about its ability to continue as a going concern despite progress in clinical trials and product launches.

Jaguar Health reported increased net losses and a significant decrease in cash for Q2 2025, despite slight revenue growth, as it continues to fund product development and commercialization efforts.

Jaguar Health's Q1 2025 results reveal a revenue decrease alongside ongoing efforts in clinical development and commercial expansion.

Jaguar Health's Q3 2024 results show a revenue increase driven by Mytesi sales, but the company continues to experience significant losses.

Jaguar Health, Inc. reported a net comprehensive loss of $54.4 million for 2025, an increase from $39.0 million in 2024, while securing $18 million in upfront non-dilutive capital from a US licensing agreement for Mytesi and Canalevia-CA1.

Jaguar Health amends its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Jaguar Health's 10-K filing highlights progress in cancer therapy-related diarrhea treatment and commercial expansion with Gelclair, while addressing ongoing financial challenges and future strategies.

Jaguar Health has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Jaguar Health's 10-K filing highlights the company's ongoing efforts in developing and commercializing plant-based pharmaceuticals for gastrointestinal issues in both humans and animals.

Jaguar Health's Director, John Micek, was granted 7,377 shares of common stock and 7,377 stock options, following two significant reverse stock splits in 2024 and 2025.

Jaguar Health's Chief of Sustainable Supply, Steven R. King, received grants of 11,740 restricted stock units and 11,740 stock options.

Jaguar Health's CEO and President, Lisa A. Conte, was granted 28,592 restricted stock units and 28,592 stock options on December 11, 2025, under the company's 2014 Stock Incentive Plan.

Jaguar Health, Inc. granted its Chief of Staff, Chief Compliance Officer, and General Counsel, Jonathan S. Wolin, 11,740 restricted stock units and 11,740 stock options.

Jaguar Health's CSO acquired 11,740 shares and options on December 11, 2025.

Jaguar Health, Inc. director James J. Bochnowski was granted restricted stock units and stock options on December 11, 2025, aligning his interests with shareholders.

Jaguar Health, Inc. is convening a Special Meeting of Stockholders to vote on critical proposals including share issuances, warrant repricing, and stock plan amendments.

Jaguar Health, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 22, 2026, to address director elections, auditor ratification, and significant equity issuances.

Jaguar Health, Inc. calls a Special Meeting to vote on increasing authorized shares, two potential reverse stock splits, and the issuance of shares for debt exchange.

Jaguar Health, Inc. calls a Special Meeting to approve the issuance of common stock related to Series N Preferred Stock exchanges and a new PIPE financing, crucial for Nasdaq compliance.

Jaguar Health, Inc. has issued a supplement to its definitive proxy statement, clarifying that Proposal 7 for its 2025 Annual Meeting is a non-routine matter under NYSE rules, impacting broker voting.

Jaguar Health, Inc. is calling its stockholders to an Annual Meeting on August 19, 2025, to vote on key proposals including the election of directors, ratification of auditors, expansion of its stock incentive plan, and approval of substantial common stock issuances from preferred stock and convertible debt exchanges.

Jaguar Health, Inc. has filed a pre-effective amendment to its S-1 registration statement to allow for the resale of up to 41,000,000 shares of common stock by C/M Capital Master Fund, LP.

Joshua Mailman has filed a Schedule 13G, disclosing beneficial ownership of 189,617 shares, representing 9.99% of Jaguar Health, Inc.'s common stock.

Lincoln Alternative Strategies LLC reports zero beneficial ownership in Jaguar Health, Inc. common stock, signaling a complete divestment or reduction below the 5% reporting threshold.

Joshua Mailman has reported a beneficial ownership of 8.4% of Jaguar Health, Inc.'s common stock, totaling 587,320 shares.

Streeterville Capital LLC and related entities report 0% beneficial ownership in Jaguar Health, Inc., indicating a full divestment of their previously reported stake.

Iliad Research & Trading, L.P. and affiliated entities have disclosed a 9.8% beneficial ownership stake in Jaguar Health, Inc. common stock.

CVI Investments, Inc. and Heights Capital Management, Inc. disclose a 4.6% beneficial ownership stake in Jaguar Health, Inc. common stock.